Inspection Machines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The inspection machines market size is projected to be USD 32.5 billion in 2025, USD 34.62 billion in 2026, and reach USD 47.51 billion by 2031, growing at a CAGR of 6.53% from 2026 to 2031. This report is Segmented by Product (Vision Inspection Systems, and More), Machine Type (Fully-Automated, and More), Packaging Type (Ampoules, and More), End User (Pharmaceutical Manufacturers, Biotechnology Companies, and CROs & CDMOs), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Inspection Machines Market Trends and Insights

Stringent Regulatory Compliance Requirements

Regulators are intensifying inspection protocols to address data-integrity issues and restore trust in the drug manufacturing process. In 2024, the FDA conducted 621 foreign inspections, marking a 28% increase from 2023, and issued 105 warning letters targeting unvalidated automated systems under 21 CFR Part 11. In January 2025, China’s NMPA updated GMP Annex 1, requiring 100% automated visual inspection for parenterals and proof of statistical control across three consecutive validation batches. Additionally, the EMA’s EUDAMED database, launched in May 2025, now links adverse-event reports to plant identifiers, increasing scrutiny of facilities with high reject ratios. To comply with these evolving regulations, vendors are integrating time-stamped audit-trail modules that record every image, decision, and operator override. These measures help companies address FDA Form 483 citations and maintain ISO 13485 certification. The regulatory demands are driving retrofits in legacy plants and accelerating capital investments in new facilities, particularly among CDMOs managing multiple sponsor quality systems.

Rising Global Product Recall Incidents

In fiscal 2024, the FDA initiated 260 drug recalls, primarily driven by labeling errors, particulate contamination, and container-closure failures. Class I recalls accounted for 18% of these cases, up from 12% in 2023. A notable recall in January 2025 involved 1.2 million epinephrine syringes due to contamination with glass fragments, prompting the implementation of laser-diffraction counters and stricter reject verification protocols. Regulatory responses to nitrosamine contamination incidents from 2019 to 2023 have led to mandates for hyperspectral near-infrared spectroscopy to confirm active pharmaceutical ingredients (APIs), addressing limitations in standard vision systems. The financial impact of a single Class I recall can exceed USD 50 million, including product recall costs, fines, and lost sales. Consequently, investments in AI-enabled inspection lines, often costing over USD 3 million, are increasingly justified. Additionally, insurers are adjusting liability premiums based on the validation status of inspection systems, further incentivizing manufacturers to adopt advanced analytics and online statistical process control.

Availability of Lower-Cost Refurbished Equipment

Integrated inspection lines, combining vision, X-ray, and weighing technologies, are priced at over USD 5 million. Implementing full IQ-OQ-PQ protocols, in line with FDA 21 CFR Part 11, EU Annex 11, and ISO 13485, typically requires 12-18 months. Consequently, cost-sensitive generic manufacturers are opting for semi-automated benches priced between USD 100,000 and USD 300,000, though these systems lack serialization capabilities. Refurbished systems, offered at 40%-50% discounts, drive fragmented demand across Latin America, the Middle East, and parts of the Asia-Pacific. However, challenges such as parts shortages and software obsolescence pose risks to audit readiness. Establishing statistical equivalence across ampoules, vials, and syringes increases the need for additional camera setups, lighting profiles, and defect libraries. This complexity gives large multinationals with dedicated validation teams a competitive edge, further widening the technology gap between tier-1 and tier-2 firms.

Other drivers and restraints analyzed in the detailed report include:

• Growing Adoption of Production-Line Automation
• Increased Implementation of Pharmaceutical Serialisation Programs
• Cyber-Security Concerns in Connected Inspection Ecosystems

Segment Analysis

X-ray systems are forecast to grow at an 8.54% CAGR, eclipsing the 6.53% pace of the overall inspection machines market, because regulators now require 100% container-closure-integrity checks for lyophilized oncology and gene-therapy vials. Vision inspection dominated the inspection machines market with 32.65% market share in 2025, given its breadth across cosmetic and label tasks, but its inability to detect subsurface cracks is ceding ground to dual-energy X-ray platforms such as Mettler-Toledo’s X38, which scans 400 syringes per minute.

Laser-diffraction particle counters and hyperspectral imagers command high price premiums, confining uptake to biologics and counterfeit-detection lines. Leak testers using vacuum decay or helium mass spectrometry remain niche for now due to slow cycle times. Combination checkweigher-vision-X-ray units appeal to CDMOs seeking narrow footprints and simplified validation, with WIPOTEC-OCS booking a 42% rise in 2025 orders.

Fully automated equipment held 56.43% inspection machines market size in 2025 and is projected to post an 8.21% CAGR to 2031 as Western labor inflation makes robotic loading attractive for batches above 50,000 units. Removing three to four operators per shift saves USD 300,000-USD 500,000 annually in Europe and USD 150,000-USD 250,000 in the U.S., offsetting capex quickly.

Semi-automated rigs suit mid-volume generics producers constrained by budget yet wary of manual inspection’s compliance risks. Benchtop systems under USD 150,000 remain relevant for clinical-trial material but lack electronic audit trails and serialization hooks, limiting scalability. Retrofit kits that bolt AI vision onto semi-automated frames help owners extend asset life while improving data integrity.

Complete Report Scope:

• By Product
  • Vision Inspection Systems
  • X-Ray Inspection Systems
  • Leak-Detection Systems
  • Metal Detectors
  • Combination Checkweigher-Vision-X-Ray Systems
  • Other Inspection Systems
• By Machine Type
  • Fully-Automated
  • Semi-Automated
  • Manual / Benchtop
• By Packaging Type
  • Ampoules
  • Vials
  • Blister Packs
  • Syringes & Cartridges
  • Bottles & Containers
• By End User
  • Pharmaceutical Manufacturers
  • Biotechnology Companies
  • CROs & CDMOs
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 42.76% of global revenue in 2025, buoyed by the DSCSA’s serialization deadline and BIOSECURE Act incentives that steered fill-finish contracts to domestic CDMOs. Seven Mexican greenfield projects announced in 2024-2025 will install over USD 200 million in automated inspection by 2027, while Canada leverages regulatory harmonization to streamline validation.

Asia-Pacific is set to log the fastest 7.43% CAGR to 2031, driven by China’s December 2026 serialization cutoff and India’s goal to add 200 WHO-prequalified injectable sites by 2028. Japan and South Korea deploy AI analytics to mitigate labor shortages and sustain biologics exports, whereas capital constraints and refurbished imports shape demand in Southeast Asia.

Europe represented roughly 28% of 2025 sales. Germany leads Industry 4.0 integration, yet IEC 62443 cyber rules add USD 200,000-USD 500,000 per line. The U.K.’s post-Brexit divergence doubles validation for dual-market suppliers, and southern Europe upgrades legacy vision systems to meet FMD codes. The Middle East, Africa and South America remain emerging territories, balancing price with compliance through semi-automated or refurbished purchases.

List of Companies Covered in this Report:

• ACG Worldwide
• Anritsu Corporation
• Antares Vision Group
• Brevetti CEA SpA
• CMP Phar.ma
• Cognex
• Ishida Co. Ltd
• Jekson Vision
• Keyence Corporation
• Körber AG (Seidenader)
• Mettler Toledo
• Minebea Intec
• OMRON
• OPTEL Group
• Sesotec GmbH
• TapTone (Teledyne)
• Teledyne Technologies
• Thermo Fisher Scientific
• Uhlmann Pac-Systeme
• WIPOTEC-OCS

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support